Command Palette

Search for a command to run...

sandu-pharmaceuticals

44.97+0.65%
Market Cap
₹43.17 Cr
Stock P/E
27.81
ROCE
5.35%
ROE
3.66%
Book Value
₹43.49

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Sandu Pharmaceuticals Ltd. shows potential in the context of profitability and growth compared to its peers, although its financial metrics indicate it is underperforming in valuation and efficiency. Companies like Cipla and Dr. Reddy's demonstrate stronger profitability and valuation attractiveness, while Sandu's low debt level is a positive aspect in a sector where many companies exhibit higher leverage.

Key Points
  • Sandu Pharmaceuticals has a low debt-equity ratio of 0, indicating no reliance on debt financing.
  • The company shows a low ROE of 3.66%, suggesting less efficiency in generating profits compared to peers.
  • With a PE ratio of 29.42, Sandu is relatively expensive compared to peers like Dr. Reddy's, which has a PE of 15.50.
Top Performers
Cipla Ltd.

Strong revenue growth of 13.28% YoY and the lowest PE ratio among peers, indicating good valuation.

Dr. Reddy's Laboratories Ltd.

High ROE of 21.76% and a very low PE of 15.50, making it an attractive investment.

Mankind Pharma Ltd.

Exceptional revenue growth of 18.12% YoY and solid profitability metrics.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.